P/E ratio for Intellia Therapeutics (NTLA)
P/E ratio as of April 2024 (TTM): -3.88
According to Intellia Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.87729. At the end of 2022 the company had a P/E ratio of -5.65.
P/E ratio history for Intellia Therapeutics from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.65 | -82.05% |
| 2021 | -31.4 | 38.74% |
| 2020 | -22.7 | 227.56% |
| 2019 | -6.92 | 0.88% |
| 2018 | -6.86 | -33.62% |
| 2017 | -10.3 | -14.47% |
| 2016 | -12.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.71 | -4.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.